Stephens Reiterates “Overweight” Rating for Hologic (NASDAQ:HOLX)

Stephens restated their overweight rating on shares of Hologic (NASDAQ:HOLX) in a research report report published on Tuesday morning, Benzinga reports. The firm currently has a $92.00 target price on the medical equipment provider’s stock.

A number of other equities analysts also recently issued reports on the company. Argus increased their price target on Hologic from $89.00 to $95.00 and gave the stock a buy rating in a research report on Thursday, May 9th. StockNews.com upgraded Hologic from a hold rating to a buy rating in a research report on Friday, May 3rd. Evercore ISI increased their price target on Hologic from $76.00 to $78.00 and gave the stock an in-line rating in a research report on Tuesday. Royal Bank of Canada increased their price target on Hologic from $81.00 to $82.00 and gave the stock a sector perform rating in a research report on Tuesday. Finally, Citigroup upgraded Hologic from a neutral rating to a buy rating and increased their price target for the stock from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Four analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average price target of $87.60.

Hologic Stock Up 0.5 %

Shares of HOLX opened at $83.64 on Tuesday. Hologic has a 52 week low of $64.02 and a 52 week high of $84.15. The company has a quick ratio of 3.29, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $19.43 billion, a price-to-earnings ratio of 42.67, a PEG ratio of 2.59 and a beta of 0.99. The stock’s 50-day moving average price is $75.33 and its 200-day moving average price is $75.32.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the prior year, the business earned $0.93 earnings per share. The company’s revenue was up 2.7% compared to the same quarter last year. On average, sell-side analysts predict that Hologic will post 4.08 EPS for the current year.

Insider Activity at Hologic

In related news, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total transaction of $294,237.36. Following the transaction, the chief executive officer now owns 1,157,562 shares in the company, valued at $92,755,443.06. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total transaction of $294,237.36. Following the transaction, the chief executive officer now owns 1,157,562 shares in the company, valued at $92,755,443.06. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Christiana Stamoulis sold 9,039 shares of Hologic stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the transaction, the director now owns 45,472 shares in the company, valued at approximately $3,615,024. The disclosure for this sale can be found here. Insiders own 1.75% of the company’s stock.

Institutional Investors Weigh In On Hologic

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Innealta Capital LLC purchased a new stake in Hologic in the second quarter valued at $25,000. iA Global Asset Management Inc. purchased a new stake in Hologic in the first quarter valued at $37,000. Allworth Financial LP raised its position in Hologic by 39.3% in the fourth quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 179 shares during the period. Mather Group LLC. purchased a new stake in Hologic in the first quarter valued at $48,000. Finally, Massmutual Trust Co. FSB ADV raised its position in Hologic by 24.7% in the first quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after purchasing an additional 137 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.